<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136012">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694680</url>
  </required_header>
  <id_info>
    <org_study_id>NWT-02/Human 4</org_study_id>
    <nct_id>NCT01694680</nct_id>
  </id_info>
  <brief_title>Intervention Trial in Early Age-related Macular Degeneration</brief_title>
  <acronym>I-TEAM</acronym>
  <official_title>Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newtricious R&amp;D BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Italia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Newtricious R&amp;D BV</source>
  <oversight_info>
    <authority>Europe: European Food Safety Authority (EFSA)</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the I-TEAM project is to assess whether there is a change in visual function
      and status of the retina after a year of intervention in subjects with early signs of
      Age-related Macular Degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotenoid levels</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of lutein and Zeaxanthin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Age-related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>Lutein-enriched-egg beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powder in sachet to prepare beverage</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein-enriched-egg beverage</intervention_name>
    <arm_group_label>Lutein-enriched-egg beverage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early AMD (AREDS category 2)

               -  many small drusen, or

               -  a few intermediate-sized (63-124 micrometres in diameter) drusen, or

               -  macular pigmentary changes

        OR

          -  Intermediate AMD (AREDS category 3)

               -  extensive intermediate sized (63-124 micrometres in diameter) drusen, or

               -  at least one large (&gt;125 micrometers in diameter) drusen or

               -  geographic atrophy not involving the foveal centre

          -  men and women age ≥50 years

          -  BMI 18-35 kg/m2

          -  Vision ≥ 20/40 for Snellen visual acuity

          -  lutein intake of &lt; 2 mg/day (including supplements)

          -  DHA intake of &lt; 150 mg/day (including supplements)

          -  must be able to give written informed consent

          -  have normal hematologic parameters

          -  normal values of plasma albumin

          -  normal values for liver and kidney function

          -  no use of carotenoid, fish oil, or n3 fatty acid supplements (within 1 month of study
             start)

        Exclusion Criteria:

          -  ocular media opacity (severe cataract)

          -  history of active small bowel disease or resection

          -  atrophic gastritis

          -  history of hyperlipidemia or screening values as follows (LDL &gt; 5.33mmol/L or
             205mg/dL; triglycerides &gt; 4.52mmol/L or &gt;400 mg/dL)

          -  hypertension (&gt;150/90 mm Hg)

          -  diabetes mellitus (if also accompanied by signs of diabetic retinopathy)

          -  alcohol intake of &gt;2 drinks/day or 14 drinks/week

          -  pancreatic disease

          -  dementia or Alzheimer's disease

          -  anemia, and bleeding disorders

          -  known allergy to egg or egg products

          -  known allergy to milk or milk products

          -  known allergy to cocoa or chocolate products

          -  known allergy to fish or fish oils

          -  lactose intolerance

          -  pregnancy or lactation

          -  diseases that interfere with fat absorption, e.g. colitis, celiac disease, Crohn's
             disease, cystic fibrosis (as determined by screening interview)

          -  medication or supplements that contain a significant level of carotenoids, including
             an amount of lutein of more than 0.25 mg per day within 1 month of the study start

          -  medications that interfere with fat absorption, e.g. bile sequestrants (as determined
             by screening interview)

          -  use of antipsychotic, anti manic, or dementia medications

          -  smoking or use of nicotine patches or gum (within the past 6 months)

          -  subjects having extremely high dietary intakes of carotenoids

          -  stroke, head injury with loss of consciousness or seizures

          -  for US and UK center: Non English speaking
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E J Johnson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA), Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TUFTS University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EJ Johnson, PhD</last_name>
      <phone>617-556-3204</phone>
    </contact>
    <investigator>
      <last_name>E Reichel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Augenklinik - Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Brinkmann, PhD</last_name>
      <phone>+49-1752490103</phone>
      <email>christian.brinkmann@ukb.uni.bonn.de</email>
    </contact>
    <investigator>
      <last_name>Prof F Holz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital - Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I Murray, PhD</last_name>
      <phone>+44-1613063886</phone>
      <email>ian.j.murray@manchester.ac.uk</email>
    </contact>
    <investigator>
      <last_name>I Murray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Lutein</keyword>
  <keyword>Visual function</keyword>
  <keyword>Early signs of AMD</keyword>
  <keyword>AREDS-category 2</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
